Drug intelligence / Profile preview

ofatumumab + bortezomib

Development stage: Unknown
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of ofatumumab, a monoclonal antibody, and bortezomib, a proteasome inhibitor. Bortezomib is a reversible inhibitor of the 26S proteasome that blocks the ubiquitin-proteasome pathway, preventing degradation of key proteins and inducing cell cycle arrest and apoptosis. It primarily inhibits the chymotryptic-like activity of the proteasome and suppresses the NF-κB signaling pathway. Ofatumumab is a monoclonal antibody used in treating chronic lymphocytic leukemia and multiple sclerosis.

Targets

CD20 (B-lymphocyte antigen CD20)PSMB5 (Proteasome subunit beta Type-5)PSMB6 (Proteasome 20S subunit beta 6)

Beyond the preview

Go deeper on ofatumumab + bortezomib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ofatumumab + bortezomib.

Explore the full profile